| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Giulio Zuccoli | Q48356040 |
| Nicolo Pipitone | Q92155214 | ||
| Ignazio Olivieri | Q114314190 | ||
| Carlo Salvarani | Q37835033 | ||
| P2093 | author name string | Angela Padula | |
| Luigi Boiardi | |||
| Angelo Nigro | |||
| Salvatore D'angelo | |||
| P433 | issue | 2 | |
| P921 | main subject | Behçet's disease | Q911427 |
| P304 | page(s) | 285-290 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature | |
| P478 | volume | 59 |
| Q43573915 | An attack of acute neuro-Behçet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases. |
| Q58326155 | Anakinra treatment in drug-resistant Behcet’s disease: a case series |
| Q83738379 | Atypical presentation of Behçet's disease with central nervous system involvement successfully treated with infliximab |
| Q57215982 | Behcet's disease |
| Q38275100 | Behçet syndrome: from pathogenesis to novel therapies |
| Q37279367 | Behçet's disease: recent advances in early diagnosis and effective treatment |
| Q33908217 | Biological treatments in Behçet's disease: beyond anti-TNF therapy. |
| Q24187204 | Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome |
| Q43740345 | Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years |
| Q38677010 | Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study. |
| Q38173702 | Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations |
| Q37003609 | Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease: An Observational Study |
| Q42861321 | Efficacy of infliximab in neuro-Behçet's disease presenting with isolated longitudinally extensive transverse myelitis |
| Q36484399 | Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity |
| Q37856882 | Infliximab for patients with neuro-Behcet's disease: case series and literature review. |
| Q37108554 | Infliximab is a plausible alternative for neurologic complications of Behçet disease |
| Q35135028 | Limbic encephalitis associated with relapsing polychondritis responded to infliximab and maintained its condition without recurrence after discontinuation: a case report and review of the literature |
| Q53090626 | Long-term outcome of neuro-Behçet's disease. |
| Q42118312 | Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behçet's disease responding to infliximab |
| Q38786414 | Management of severe complications in Behçet's disease with TNF inhibitors. |
| Q48958519 | Neuro-Behçet disease presenting with acute psychosis in an adolescent. |
| Q27000669 | Neuro-Behçet's disease in childhood: a focus on the neuro-ophthalmological features |
| Q34927577 | Neuro-Behçet's disease: epidemiology, clinical characteristics, and management |
| Q57213283 | Neuro-behçet's disease in South Korea: clinical characteristics and treatment response |
| Q38046123 | Neurological complications of Behçet's syndrome |
| Q39173608 | Neurological complications of Behçet's syndrome |
| Q38830790 | New therapeutic solutions for Behçet's syndrome |
| Q84789509 | One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs |
| Q56974494 | Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab |
| Q85022872 | Pediatric Neuro-Behçet's Disease Responsive to Adalimumab |
| Q46346251 | Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behçets disease |
| Q43105081 | Recurrent longitudinal extensive transverse myelitis in a neuro-Behçet syndrome treated with infliximab |
| Q52148791 | Rituximab is effective in severe treatment-resistant neurological Behçet's syndrome. |
| Q45978191 | Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q37888959 | The differential diagnosis of longitudinally extensive transverse myelitis |
| Q38848128 | The potential of genetically guided treatment in Behçet's disease |
| Q48353990 | Transient involvement of the cerebral cortex in a flare of Behçet's syndrome |
| Q38063024 | Transverse myelitis |
| Q34974052 | Treatment of neuro-Behçet's disease: an update. |
| Q45327262 | Unmet need in Behcet's disease: most patients in routine follow-up continue to have oral ulcers |
| Q37624811 | Update on the Medical Management of Gastrointestinal Behçet's Disease. |
| Q37712230 | Update on the therapy of Behçet disease |
| Q38180747 | Use of infliximab and other biologics in Behçet disease |
| Q81753280 | [Diagnosis and therapy of neurological manifestations of inflammatory rheumatic diseases] |
Search more.